This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Preisler, H. D. Articles by Robin, E. Search for Related Content PubMed PubMed Citation Articles by Preisler, H. D. Articles by Robin, E.

Suppression of Telomerase Activity and Cytokine Messenger RNA Levels in Acute Myelogenous Leukemia Cells in Vivo in Patients by Amifostine and Interleukin 4¹

Department of Medicine, Division of Bone Marrow Transplantation, Hematology, and Medical Oncology, Rush Cancer Institute, Chicago, Illinois [H. D. P., B. L., J. Y., R. W. H., E. D., P. V., M. T., H. C., S. A. G., S. A., S. S., P. T.]; Cook County Hospital, Chicago, Illinois [A. J.]; Illinois Masonic Medical Center, Chicago, Illinois [A. G.]; and Ingalls Memorial Hospital, Harvey, Illinois [E. R.]

High levels of telomerase activity and high rates of cell proliferation are associated with a poor prognosis in acute myelogenous leukemia. Furthermore, cytokine production by leukemia cells is believed to play an important role in determining the proliferative characteristics of leukemia. The in vivo effects of two noncytotoxic agents on these parameters were determined in 33 acute myelogenous leukemia patients. Three daily doses of interleukin (IL) 4 or a single dose of amifostine reduced telomerase activity in the leukemia marrow cells in 7 of 9 and 11 of 13 patients, respectively. The administration of a single dose of amifostine resulted in a reduction in tumor necrosis factor and IL-6 transcript levels in the marrow cells of 10 of 13 and 12 of 13 patients in which these transcripts were present. The administration of only three doses of IL-4 or a single dose of amifostine has a significant effect on leukemia cell parameters, which are believed to have a significant impact on the in vivo biology of the disease and on its response to remission induction therapy.

This article has been cited by other articles:

				J. C. Acosta, C. Richard, M. D. Delgado, M. Horita, M. G. Rizzo, J. L. Fernandez-Luna, and J. Leon Amifostine impairs p53-mediated apoptosis of human myeloid leukemia cells Mol. Cancer Ther., September 1, 2003; 2(9): 893 - 900. [Abstract] [Full Text] [PDF]

				T. Liu, Y. Nozaki, and S. H. Phan Regulation of Telomerase Activity in Rat Lung Fibroblasts Am. J. Respir. Cell Mol. Biol., May 1, 2002; 26(5): 534 - 540. [Abstract] [Full Text] [PDF]